ESR1 and neoplasm: For example, the tumor genome has revealed several mechanisms of acquired AI resistance (8–10) such as amplifications or mutations that can activate ESR1 (10) and ligand-independent ERα activation of downstream pathways such as the phosphatidylinositol 3 kinase (11).